Publication: Factors influencing neutralizing antibody response to the original SARS-CoV-2 virus and the Omicron variant in a high vaccination coverage country, a population-based study
| dc.contributor.author | Hormazabal, Juan | |
| dc.contributor.author | Nuñez-Franz, Loreto | |
| dc.contributor.author | Rubilar, Paola | |
| dc.contributor.author | Apablaza, Mauricio | |
| dc.contributor.author | Vial Cox, María Cecilia | |
| dc.contributor.author | Cortes Salinas, Lina Jimena | |
| dc.contributor.author | González, Natalia | |
| dc.contributor.author | Vial, Pablo | |
| dc.contributor.author | Said, Macarena | |
| dc.contributor.author | Gonzalez Wiedmaier, Claudia | |
| dc.contributor.author | Olivares, Kathya | |
| dc.contributor.author | Aguilera, Ximena | |
| dc.contributor.author | Ramírez-Santana, Muriel | |
| dc.date.accessioned | 2024-05-20T12:52:57Z | |
| dc.date.available | 2024-05-20T12:52:57Z | |
| dc.date.issued | 2023 | |
| dc.description.abstract | The study compared immunity to the original SARS-CoV-2 virus (Wuhan) and the Omicron variant using neutralizing antibodies (NAbs), that provide a good approximation of protective immunity. The results might help determine immunization strategies. Design and methods: Unlike previous studies, we analyzed NAbs in a random sample of 110 IgG positive sera from individuals who participated in a population-based seroprevalence transversal study, carried out in May 2022 in two Chilean cities, a country with high vaccination coverage. Results: Our findings indicate that 98.2% of individuals had NAbs against Wuhan, 65.5% against Omicron, and 32.7% tested positive for Wuhan but not Omicron. Factors influencing protective immunity included a prior natural infection and the number of vaccines received. NAbs titers against the original virus were high, demonstrating vaccine effectiveness in the population. However, the level of antibodies decreased when measuring NAbs against Omicron, particularly among older individuals, indicating a decline in vaccine protection. Previous COVID-19 episodes acted as a natural booster, increasing NAbs titers against both virus strains. Conclusions: Protective immunity against the original Wuhan SARS-CoV-2 virus is reduced when compared to Omicron variant. Updating vaccine to target emerging variants and continued monitoring of effectiveness at the population level are necessary. | |
| dc.description.version | Versión publicada | |
| dc.format.extent | 7 p. | |
| dc.identifier.citation | Vaccine X. 2023 Aug 26;15:100372. | |
| dc.identifier.doi | https://doi.org/10.1016/j.jvacx.2023.100372. | |
| dc.identifier.uri | https://hdl.handle.net/11447/8848 | |
| dc.language.iso | en | |
| dc.rights | Atribución-NoComercial-CompartirIgual 3.0 Chile (CC BY-NC-SA 3.0 CL) | |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc-sa/3.0/cl/ | |
| dc.subject | COVID-19 | |
| dc.subject | Chile | |
| dc.subject | Immunity | |
| dc.subject | Neutralizing antibodies | |
| dc.subject | Territorial population | |
| dc.subject | Vaccine effectiveness | |
| dc.title | Factors influencing neutralizing antibody response to the original SARS-CoV-2 virus and the Omicron variant in a high vaccination coverage country, a population-based study | |
| dc.type | Article | |
| dcterms.accessRights | Acceso abierto | |
| dspace.entity.type | Publication | |
| relation.isAuthorOfPublication | d0fb8162-7e81-4714-92e6-55df118f11c3 | |
| relation.isAuthorOfPublication | eab64472-db34-4e6e-8051-ed06096d12aa | |
| relation.isAuthorOfPublication | 7c7e8f66-6dcd-45a0-b70f-34e8b5cc6baf | |
| relation.isAuthorOfPublication | 4cc9451a-447d-42c8-8e68-8669895ed0a0 | |
| relation.isAuthorOfPublication | 47c991fe-bbc8-4a49-9162-9c8d3f76a544 | |
| relation.isAuthorOfPublication | c60c673d-2a3e-4c8f-af8c-cb6efb9c4b0e | |
| relation.isAuthorOfPublication | e6efd8c7-1562-4325-8384-80eedefff054 | |
| relation.isAuthorOfPublication | dd947547-2eec-458b-890f-977f5ce56f0b | |
| relation.isAuthorOfPublication.latestForDiscovery | d0fb8162-7e81-4714-92e6-55df118f11c3 |